Altimmune slumps on mixed Phase IIb results for pemvidutide in MASH

US biopharma company Altimmune (Nasdaq: ALT) saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive’ top-line results from the IMPACT Phase IIb trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).

The clinical-stage biopharmaceutical company reported that the trial met its primary endpoint, with up to 59.1% of participants achieving MASH resolution without worsening of fibrosis in an intent-to-treat analysis. Despite this positive outcome, investors appeared concerned about other aspects of the data. For the second measure, 31.8% and 34.5% of patients who received 1.2mg and 1.8mg pemvidutide, respectively, saw an improvement in fibrosis without worsening of MASH, which was not significant versus the 25.9% rate seen with placebo.

Study details